Workgroup
Managing Opioid Use Disorder
Workgroup Members—Thank You!

**Work Group Facilitator**
Karen Drexler, MD

**Work Group Recorder**
Jennifer Burden, PhD
Ellen Edens, MD

**Work Group Members**
Arlene Bierman, MD, MS
Jennifer Burden, PhD
Kathy Carroll, PhD
Wilson Compton, MD
Neeraj Gandotra, MD
Adam Gordon, MD, MPH
Hildi Hagedorn, PhD
Christopher Jones, PharmD, DrPH
Elisabeth Kato, MD
Allison Lin, MD
James McKay, PhD
Edward Nunes, Jr., MD
Bob O’Brien, PhD
Ismene Petrakis, MD
Andrew Saxon, MD
Roger Weiss, MD
Priority Questions

1. What are the barriers and facilitators to implementing Medications for OUD (MOUD)?
2. What is the minimum monitoring necessary for effective OUD treatment?
3. What is the comparative effectiveness of psychosocial treatments for MOUD outcomes?
4. In whom, how, & when can we safely stop MOUD?
Priority Questions

1. What are the barriers and facilitators to implementing Medications for OUD (MOUD)?
2. What is the minimum monitoring necessary for effective OUD treatment?
3. What is the comparative effectiveness of psychosocial treatments for MOUD outcomes?
Priority Questions

1. What are the barriers and facilitators to implementing Medications for OUD (MOUD)?
2. What is the minimum monitoring necessary for effective OUD treatment?
3. What is the comparative effectiveness of psychosocial treatments for MOUD outcomes?
4. How do we promote sustained engagement in MOUD treatment?
Priority Question #1: Barriers and Facilitators to implementing MOUD

Results from the Evidence Synthesis Review
Priority Question #1: Barriers and Facilitators to implementing MOUD

**Patients**

**Barriers**
- Stigma
  - Social
  - Self-directed
  - Bup-specific
- Logistics
- Treatment experiences, beliefs
- Knowledge

**Facilitators**
- Positive social support from peers and family
- Support from treatment providers
- Rigid treatment structure
- Illicit buprenorphine use

**Providers**

**Barriers**
- Stigma—
  - Social
  - Perception to OUD
  - Bup-specific
- Logistics
- Knowledge
- Treatment Experiences/beliefs

**Facilitators**
- Recognition of patient need
- Access to Mentoring/Peer
- Institutional support
- Availability to specialty care
Priority Question #1: Barriers and Facilitators to implementing MOUD

System

Barriers
• Regulatory
• Policy

Facilitators
• Incentives for providers
• Communities of Practice
• Initiatives supporting MOUD
• Integrated healthcare system
• Uniform medical benefits package
Priority Question #1: Barriers and Facilitators to implementing MOUD

Knowledge Gaps: (Need for research)
• Need to understand how the barriers and facilitators identified by ESP applied to VA.
• Understanding how to intervene on stigma

Policy/Implementation Recommendations:
• Remove special privileging
• Use of clinical decision support
• Clarifying policy about perceived barriers
• Incentivize MOUD treatment
• Remove barriers to tele-prescribing
• Access to all formulations of MOUD
Priority Question #2: Minimum Monitoring Necessary

Knowledge Gaps: (Need for research)
• Unclear Role for Measurement Based Care (MBC)
• Drug use monitoring
• Frequency of clinic visits
• Role of Technology
• Machine Learning and natural language processing to support clinical practice

Policy/Implementation Recommendations:
• Provide guidance for minimum standards—1st month
• Clarifying expectations of drug screening
Priority Question #3: Comparative Effectiveness of Psychosocial Treatments (PST) for MOUD

Knowledge Gaps: (Need for research)
• Comparative effectiveness of individual v group tx in MOUD
• Utilization of community supports
  • Peer support
  • Family support
• Impact of MM structure on comparative effectiveness of PST
• Is PCMHI a facilitator to MOUD? Could we optimize with training?

Policy/Implementation:
• Clarify PST requirements should not be a barrier to MOUD.
• Supporting implementation of Contingency Mngt (CM)
Priority Question #5: Sustained Engagement in MOUD treatment

Knowledge Gaps: (Need for research)
• How do we implement chronic disease management for MOUD?
• Understand why people are discontinuing
• What are the necessary indicators to consider stopping MOUD (2+years). Is this advised even then?
• Can technology facilitate sustained or re-engagement?

Policy/Implementation:
• Efforts to reengage early drop outs.
• Overdose--expected reporting and follow-up
• Leverage lessons learned from suicide prevention
Research questions:

1. STIGMA: What interventions are effective to address the impact of stigma?
2. TECHNOLOGY: Can mobile health technology (MHT) improve MOUD outcomes? What should these MHT target? (e.g. craving, CBT interventions)
3. PEER SUPPORT—Understand the direct impact of specific types of peer support on recovery outcomes.
4. MEASUREMENT BASED CARE - Can we optimize treatment outcomes using MBC? What are the best metrics for OUD quality care?
Research questions:

5. IMPLEMENTATION & SUSTAINMENT- What are clinic & individual factors in VA that are barriers and facilitators of MOUD?

6. SCOUTT- How can we leverage SCOUTT for more research questions? What are core components of MM are sufficient for successful outcomes of MOUD?
Policy Recommendations

1. Overdose follow-up and reporting—
   • Leverage knowledge gained from suicide prevention strategies to implement mandated reporting and follow-up of overdose events

2. Policy clarification to remove barriers to timely & sustained MOUD access
   • Retain patients in MOUD and address substance use with guideline concordant care
   • Same day access is aspirational
   • Teleprescribing – clarify regulations
3. Offer ALL FDA-approved medications to all patients with OUD. Develop decision support tools
   • Expedite formulary approval for MOUD
4. National Consultation Team for SUD treatment modeled after other successful consultation programs
Recommendations for DATA

- Better integration of VA and non VA datasets
  - Standardization of laboratory test reporting
- Consensus on important outcome measures
  - Definition of retention
  - Quality of life
- Consensus on definition of quality care in MOUD treatment
  - Specific psychosocial interventions